Best of the Blog: PharmExec's 10 Most Read Stories in 2013

Happy New Year! We at PharmExec are looking forward to a busy and hopefully fortuitous 2014. For our colleagues in the Northeast bracing for yet another snow storm – and for those of you with better short-term environmental prospects – here are the 10 most-read stories published on PharmExec‘s blog during 2013, in case you missed them:

1. The List So Far: FDA Breakthrough Designations 2.Ever Bullish, Al Mann Says Afrezza is Coming in 2014 3. Teva Joins Top 20: Face of Big Pharma Changes 4. Gov’t Shutdown Halts FDA Product Submissions   5.Market Access is Dead: Patien Access is the New 6. Rx Brand Managers: Will Your Products Be Covered 7. The Sunshine Act Makes for Gloomy Sales Reps 8. The Patent Black Label: Six Side Effects o India 9. The Yin and Yang of the Court Decision on 10. How to Win in the Diabetes Space 11. Ibrutinib’s Breakthrough to Market 12. The Curious Case of AstraZeneca v. ACE 13. The Rx Industry, PBMs and Obamacare 14. What Key Opinion Leaders Really Want from Pharma 15. The African Markets Pharma Can’t Ignore

1. The List So Far: FDA Breakthrough Designations

2.Ever Bullish, Al Mann Says Afrezza is Coming in Mid-April

3. Teva Joins Top 10: ‘Face’ of Big Pharma Changing

4. Gov’t Shutdown Halts FDA Product Submissions and Other Functions

5. Market Access is Dead: Patient Access is the New Prescription for Health

6. Rx Brand Managers: Will Your Products Be Covered Under Obamacare?

7. The Sunshine Act Makes for Gloomy Sales Reps

8. The Patent Black Label: Six Side Effects of India’s Novartis Glivec Ruling

9. The Yin and Yang of the Court Decision on HCR

10. How to Win in the Diabetes Space